Altimmune Inc (ALT)

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood...

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage...

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesBioMedWire Editorial Coverage: Obesity and...

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes...

Form 8-K - Current report

Altimmune Announces First Quarter 2026 Financial Results and Business Update

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents...

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL...

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities